Vivjoa (Oteseconazole) Patent Expiration, LOE Window & CMS Spending

Vivjoa (Oteseconazole) by Mycovia: FDA Orange Book core substance LOE 2036-03-17, 0 AB generics, $551K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMycovia
FDA Application & PathwayN215888 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-03-17
Last Listed Patent or Exclusivity Date2036-03-17
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$551K
2024 Medicare Part D Spend$323K
2024 Medicaid Spend$228K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel